Wipfli Financial Advisors LLC Buys Shares of 200,000 Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Wipfli Financial Advisors LLC Buys Shares of 200,000 Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Wipfli Fiscal Advisors LLC acquired a new stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Score) through the 3rd quarter, in accordance to the organization in its most modern disclosure with the SEC. The fund bought 200,000 shares of the biopharmaceutical firm’s stock, valued at close to $63,000. Wipfli Money Advisors LLC owned close to .11{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of Akebia Therapeutics at the close of the most recent reporting period of time.

Various other institutional buyers and hedge funds also a short while ago purchased and sold shares of AKBA. Mirabella Financial Solutions LLP bought a new stake in shares of Akebia Therapeutics in the 1st quarter valued at about $40,000. MetLife Investment decision Management LLC lifted its holdings in Akebia Therapeutics by 176.6{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the 1st quarter. MetLife Financial commitment Administration LLC now owns 85,186 shares of the biopharmaceutical company’s inventory worth $61,000 soon after obtaining an additional 54,389 shares in the course of the very last quarter. BNP Paribas Arbitrage SA lifted its holdings in Akebia Therapeutics by 123.7{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company’s stock truly worth $32,000 just after purchasing an added 50,066 shares all through the past quarter. XTX Topco Ltd lifted its holdings in Akebia Therapeutics by 282.7{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the 1st quarter. XTX Topco Ltd now owns 102,392 shares of the biopharmaceutical company’s inventory well worth $74,000 just after acquiring an further 75,635 shares all through the previous quarter. Ultimately, Virtu Economic LLC acquired a new stake in Akebia Therapeutics in the 1st quarter truly worth somewhere around $94,000. Hedge funds and other institutional traders individual 28.13{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the firm’s stock.

Akebia Therapeutics Investing Up .7 {21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}

Shares of NASDAQ AKBA opened at $.70 on Friday. The business has a fifty day very simple transferring ordinary of $.40 and a 200 day uncomplicated shifting normal of $.37. The organization has a marketplace capitalization of $127.85 million, a price tag-to-earnings ratio of -.79 and a beta of .88. Akebia Therapeutics, Inc. has a a person yr small of $.24 and a just one yr substantial of $2.93.

Akebia Therapeutics (NASDAQ:AKBA – Get Rating) previous issued its earnings results on Thursday, November 3rd. The biopharmaceutical business documented ($.28) EPS for the quarter, lacking analysts’ consensus estimates of ($.15) by ($.13). The business experienced earnings of $48.96 million during the quarter, when compared to analyst estimates of $47.17 million. Akebia Therapeutics had a damaging web margin of 52.42{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and a detrimental return on equity of 315.92{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. On average, research analysts anticipate that Akebia Therapeutics, Inc. will put up -.59 earnings for each share for the current fiscal yr.

Analyst Scores Alterations

Individually, StockNews.com initiated coverage on Akebia Therapeutics in a report on Monday, January 2nd. They established a “obtain” rating for the corporation. Six analysts have rated the inventory with a maintain score and a single has assigned a purchase ranking to the firm. According to data from MarketBeat.com, the stock presently has a consensus rating of “Maintain” and an common focus on price tag of $1.75.

About Akebia Therapeutics

(Get Rating)

Akebia Therapeutics, Inc, a biopharmaceutical organization, focuses on the enhancement and commercialization of therapeutics for patients with kidney ailments. The firm’s direct item investigational product or service prospect is vadadustat, an oral therapy, which is in Phase III enhancement for the cure of anemia thanks to serious kidney condition (CKD) in dialysis-dependent and non-dialysis dependent adult patients.

Advised Tales

Want to see what other hedge money are holding AKBA? Visit HoldingsChannel.com to get the most current 13F filings and insider trades for Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Score).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

This immediate information warn was created by narrative science technologies and money info from MarketBeat in buy to present visitors with the fastest and most precise reporting. This tale was reviewed by MarketBeat’s editorial team prior to publication. Remember to ship any inquiries or reviews about this story to speak [email protected].

Right before you consider Akebia Therapeutics, you will want to listen to this.

MarketBeat retains observe of Wall Street’s major-rated and ideal doing analysis analysts and the stocks they advocate to their clientele on a each day basis. MarketBeat has discovered the five stocks that best analysts are quietly whispering to their consumers to purchase now prior to the broader industry catches on… and Akebia Therapeutics wasn’t on the list.

Though Akebia Therapeutics at present has a “Hold” score amid analysts, leading-rated analysts feel these five stocks are improved buys.

Look at The Five Stocks Below


Minnie Arwood

Next Post

RIA Edge Roundup: $12.6B+ in Assets on the Move

Mon Jan 16 , 2023
Registered investment advisors announced several deals this week, picking up fresh capital and switching broker/dealers. Here’s a look at more than $12.6 billion in client assets on the move as industry dealmakers remain undaunted by volatile markets. Cerity Partners Completes $4.8B Merger With ARGI Financial In its first M&A deal […]
RIA Edge Roundup: .6B+ in Assets on the Move

You May Like